TME-Match™: Predictive Tumor Intelligence Platform
Unlocking the Tumor Microenvironment for Smarter Clinical Decisions
Accelerate Oncology Drug Development with Data-Driven Precision
In today’s fiercely competitive oncology clinical development landscape, the ability to make smarter, faster, and more precise clinical decisions is what separates industry leaders from the rest. The Cancer Genome Atlas (TCGA) offers an unrivaled repository of tumor data, empowering biopharma organizations to move beyond conventional trial design and guesswork.
TME-Match™ is a cutting-edge solution that reconstructs the full tumor microenvironment—including immune and non-immune signals—across more than 6,900 TCGA tumor samples. This holistic approach empowers customers working with Syneos Health to identify solid tumors most likely to respond to therapies, streamlining early development and clinical planning.
Want to know where your therapy will succeed? The right match changes everything—let’s find it early with TME-Match™.
Key Benefits of TME-Match™ by Syneos Health
Increase Success Through Informed Clinical Design
Most therapies fail in early phases due to poor tumor type selection. TME-Match™ helps you pinpoint the tumor types and patient populations most likely to respond before and throughout clinical investment, reducing costly trial iterations.
Traditional methods rely on limited biomarkers and literature. TME-Match™ analyzes thousands of tumor samples to deliver quantitative, mechanistic insights, enabling confident, evidence-based decisions.
Direct resources to high-potential programs, reduce drug development failures, and avoid unnecessary trial iterations by identifying the right indications from the start.
Powered by scale and science
6,900+
TCGA tumor samples
21
solid tumor types
~19,000
genes analyzed using correlation-based methods
25
tumor ecosystem gene clusters reconstructed
Matching the right tumors to the right therapy
- Select the right tumor types before clinical investment
- Reduce trial risk with targeted combination treatments
- Enroll the right patients with biomarker precision
Related Content
Looking for exclusive insight?
